Table 1.
PTEN Lesions (Deletion and/or Mutation) in Sporadic Human Malignancies
| Site | Tumor type | PTEN inactivation | Comment | Reference no. | |
|---|---|---|---|---|---|
| Range | Average | ||||
| Brain | Glioblastoma | 17–70% | 48% (107/224) | Mostly LOH | 10–15 |
| Breast | Ductal carcinoma | 15–48% | 37% (37/100) | Mostly LOH | 6, 7 |
| Endometrium | Endometrioid carcinoma | 34–83% | 42% (139/334) | LOH and mutation | 16–21 |
| Prostate | Adenocarcinoma | 17–41% | 33% (49/149) | Mostly LOH | 43, 45, 46 |
| Ovary | Cystadenocarcinoma | 6–45% | 33% (65/198) | LOH and mutation | 1, 22–24, 47 |
| Skin | Melanoma | 32–33% | 33% (18/55) | Mostly LOH | 8, 9 |
| Thyroid | Carcinoma | 37% | 37% (19/51) | Mostly LOH | 44 |
LOH, loss of heterozygosity.